deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01598298

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Breast Cancer Musculoskeletal Complications Pain
Interventions duloxetine hydrochloride placebo
Updated 17 times since 2017 Last updated: Dec 14, 2022 Started: May 15, 2013 Primary completion: Dec 1, 2016 Completion: Dec 20, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and Musculoskeletal Complications and is currently completed. National Cancer Institute (NCI) leads this study, which shows 17 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Jan 2023 · 24 months · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2023 — May 2023 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Jan 2021 — Jan 2023 [monthly]

    Completed PHASE3

  2. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jan 2020 — Feb 2020 [monthly]

    Completed PHASE3

  4. Jul 2019 — Jan 2020 [monthly]

    Completed PHASE3

  5. May 2019 — Jul 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  6. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Completed → Active Not Recruiting

  8. Dec 2017 — Mar 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  9. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Mar 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States , Akron, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Amarillo, United States , American Fork, United States , Ames, United States , Anacortes, United States , Anchorage, United States and 443 more locations